GSK posts higher first-quarter core profit driven by specialty medicine sales
Updated
Updated · The Wall Street Journal · Apr 29
GSK posts higher first-quarter core profit driven by specialty medicine sales
16 articles · Updated · The Wall Street Journal · Apr 29
GSK reported Q1 2026 core operating profit of £2.65 billion, up from £2.53 billion a year earlier, surpassing analyst consensus of £2.46 billion.
Turnover rose 5% to £7.63 billion, with strong sales in HIV, cancer, and immune disease medicines. The company reaffirmed its 2026 guidance, expecting turnover growth of 3%-5% and profit growth of 7%-9%.
GSK plans a total 2026 dividend of 70 pence per share. Last year, the company reported turnover of £32.67 billion and core operating profit of £9.78 billion, reflecting ongoing momentum in specialty pharmaceuticals.
With its stock soaring, is GSK becoming the new leader in specialty pharma?
How will US price negotiations affect profits from GSK's top specialty medicines?
Can GSK's pipeline outrun the 2028 patent cliff for its blockbuster HIV drugs?
When will GSK’s revolutionary twice-yearly HIV treatment be available for patients?
As specialty drug sales boom, can GSK still afford to tackle antimicrobial resistance?
How does GSK's strategy hedge against the IRA's 'pill penalty' on new drugs?